LYCOS RETRIEVER 
Lexapro: Treatment
built 673 days ago
Sales in the quarter included $603,454,000 of Lexapro(R) (escitalopram oxalate), an SSRI indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults. This represents growth of 11% from the year-ago period. Sales of Namenda(R), an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, totaled $218,735,000 in the quarter, growth of 26% from reported sales of $173,881,000 in last year's third quarter. Product wholesalers collectively held more inventory of both Lexapro and Namenda at the end of the December quarter which positively impacted sales of these products by approximately $23,000,000 for Lexapro and $5,000,000 for Namenda. Wholesaler inventory levels for both products are currently at approximately two weeks of sales.
Source:
The randomized clinical trial compared the efficacy and tolerability of a fixed dose of Lexapro (escitalopram) 10 mg/day with Zoloft (sertraline) optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder. No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50-200 mg/day. At these doses, both Lexapro (escitalopram) and Zoloft (sertraline) were generally well tolerated.
Source:
MORE ABOUT
Treatment